Krystal Biotech Inc at William Blair Growth Stock Conference Transcript
Good morning. My name is Tim Lugo. For those of you I haven't met, I'm the head of biotech research here at William Blair.
And before we get too deeply into the discussion with Krish Krishnan, CEO of Krystal Biotech, as well as Meg Dodge -- thank you for joining us -- Head of Investor Relations at Krystal Biotech. And before we get too deep into it, you must check williamblair.com for all relevant disclosures.
I just want to note, before Krish's presentation, it's a great time for an investor to be looking at Krystal Biotech. Recent FDA approval should bring the first topical gene therapy to a very needy population, the DEB patient. It's a horrible disease.
It's great that Krish and the team at Krystal has developed this therapy for what is a very needy population. They're going to be launching their drug currently, I believe. And Krish will tell us all about how he's bringing this to change patients' lives over the next year.
So with that, I'd love to welcome Krish from Krystal Biotech.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |